Article thumbnail

Predictive role of plasma vascular endothelial growth factor for the effect of celecoxib in advanced non-small cell lung cancer treated with chemotherapy

By Sverre Sorenson, Helena Fohlin, Andrea Lindgren, Magnus Lindskog, Bengt Bergman, Christer Sederholm, Lars Ek, Kristina Lamberg and Birgitta Clinchy

Abstract

Aim of the study: The primary purpose of this study is to investigate if pretreatment plasma levels of vascular endothelial growth factor (VEGF) are predictive of the effect of celecoxib on survival in advanced non-small cell lung cancer (NSCLC) treated with palliative chemotherapy. A secondary objective is to describe the course of plasma VEGF levels during and after treatment with cytotoxic chemotherapy combined with celecoxib or placebo. Methods: In a previously published double-blind multicenter phase III trial, 316 patients with NSCLC stage IIIB or IV and World Health Organisation (WHO) performance status 0-2 were randomised to receive celecoxib 400 mg b.i.d. or placebo in combination with two-drug platinum-based chemotherapy. Chemotherapy cycle length was three weeks and planned duration of chemotherapy was four cycles. Celecoxib was given for a maximum of one year but was stopped earlier in case of disease progression or prohibitive toxicity. In a subset of patients, plasma VEGF levels were examined at onset of treatment and at 6, 12 and 20 weeks. Results: VEGF levels at start of treatment were obtained in 107 patients at four study sites. The median value was 70 pg/ml. Mean values declined during the first 12 weeks and then increased at 20 weeks. A subpopulation treatment effect pattern plot (STEPP) analysis showed an inverse relationship between initial plasma VEGF and the impact of celecoxib on survival with zero effect at 200 pg/ml. The effect on survival by celecoxib in the whole subset of patients was positive (hazard ratio (HR)=0.64 [confidence interval (CI) 0.43-0.95], p=0.028). Conclusion: Low pretreatment plasma levels of VEGF appear to be predictive of a positive effect of celecoxib on survival. (C) 2012 Elsevier Ltd. All rights reserved

Topics: Respiratory Medicine and Allergy, Non-small cell lung cancer, Celecoxib, Chemotherapy, Survival, Plasma, VEGF
Publisher: 'Elsevier BV'
Year: 2013
DOI identifier: 10.1016/j.ejca.2012.07.032
OAI identifier: oai:lup.lub.lu.se:d8ccfc3f-d411-4edf-9178-c027644019ae
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://dx.doi.org/10.1016/j.ej... (external link)
  • https://lup.lub.lu.se/record/3... (external link)
  • Suggested articles


    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.